FDA, Hympavzi
Medical Xpress · 2d
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors.
pharmaphorum · 3d
Pfizer rounds out haemophilia portfolio with FDA approval
The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, which was approved by the FDA in April, as well as its range of recombinant clotting factor replacement products.
YAHOO!Finance · 6d
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors,
Results that may be inaccessible to you are currently showing.
Hide inaccessible results